Nektar Therapeutics (NKTR)
Nektar Therapeutics Revenues: 17.95M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
NKTR Revenues Rankings
| Overall | 20th percentile | 3521 of 4432 |
| Sector | 42nd percentile | 270 of 470 in Healthcare |
| Industry | 61st percentile | 51 of 132 in Biotechnology |
NKTR Revenues Range, Past 5 Years
| Minimum | 9.711M | Mar 2009 |
| Maximum | 65.92M | Jun 2007 |
| Average | 29.93M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these NKTR related companies
NKTR News
Notable Analyst Rating Changes 05/24: (PPG) (WPI) (DUK) Upgraded; (BHI) (HGSI) (COG) Downgraded
May 24, 11:25AM Street Insider
May 24, 11:25AM Street Insider
Jefferies Starts Dendreon (DNDN) at Underperform, Nektar (NKTR) at Buy
May 22, 5:21PM Street Insider
May 22, 5:21PM Street Insider
Listen to $NKTR Q1 2012 earnings call - live at 05:00 PM, ondemand after - http://stks.co/3dPo
about 28 days ago by earningscast
about 28 days ago by earningscast
Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
May 02, 4:15PM PR Newswire
May 02, 4:15PM PR Newswire
$NKTR filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3aex
about 30 days ago by MarketBrief
about 30 days ago by MarketBrief
RT @BenCBanks $WHR looks good too now, and so does $NKTR (if it beraks)
about 37 days ago by Mortiman
about 37 days ago by Mortiman
$NKTR - beatiful set up in my opinion. #bullmarket #shortsqueeze http://chart.ly/nj9y29p
about 37 days ago by BenCBanks
about 37 days ago by BenCBanks
Listen to $NKTR investor and analyst r&d day - live at 12:00 PM, ondemand after - http://stks.co/3MZF
about 45 days ago by earningscast
about 45 days ago by earningscast
$NKTR released news of the partnership with $AFFY FDA approval on anemia drug.Technical setup shows momentum.I'm expecting a pop today.
about 64 days ago by stellarpicks
about 64 days ago by stellarpicks
Strong move in $NKTR today. I profiled the peculiar technical setup last night in this post: http://stks.co/36CZ
about 65 days ago by chessNwine
about 65 days ago by chessNwine
$NKTR going green. Waiting for $AFFY to explode to go along with the ride. Keep our fingers crossed with FDA decision today.
about 65 days ago by stellarpicks
about 65 days ago by stellarpicks
$NKTR has two lotto plays.$AFFY is the bigger of the two drugs. I see pullback in the morning from MAPP results, then rally rest of day.
about 65 days ago by stellarpicks
about 65 days ago by stellarpicks
NEW POST: "Wolf in Sheep's Dojis" http://stks.co/35YB $IBB $NKTR $QQQ $SPY $STUDY
about 65 days ago by chessNwine
about 65 days ago by chessNwine
RT @GArgondizza @odyssea WEIRD <<<I know so wht now $NKTR up AH after this release I dont trust it>>
about 65 days ago by odyssea
about 65 days ago by odyssea
$NKTR weak on rumored $MAPP FDA rejection, would get royalties if approved. Watch for action when official $MAPP PR comes.
about 66 days ago by TradeHawk
about 66 days ago by TradeHawk
Nektar Consolidates Research at Its State-of-the-Art R&D Center Located in San Francisco at Mission Bay
Mar 20, 10:15AM PR Newswire
Mar 20, 10:15AM PR Newswire
Nektar Therapeutics Reports Fourth Quarter and Year-End 2011 Financial Results
Feb 29, 4:15PM PR Newswire
Feb 29, 4:15PM PR Newswire
Nektar (NKTR) to Sell Royalties for CIMZIA, MIRCERA to Royalty Pharma for $124M
Feb 29, 9:06AM Street Insider
Feb 29, 9:06AM Street Insider
Nektar (NKTR) reports agreement to sell Cimzia(R) and Mircera(R) royalties to Royalty Pharma for $124M
Feb 29, 8:31AM Street Insider
Feb 29, 8:31AM Street Insider
UPDATE: Bank of America Downgrades Nektar Therapeutics to Underperform, Maintains $6 PT
Jan 20, 9:02AM Benzinga
Jan 20, 9:02AM Benzinga
BofA/Merrill Lynch Downgrades Nektar Therapeutics (NKTR) to Underperform
Jan 20, 7:02AM Street Insider
Jan 20, 7:02AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| NKTR | 6.87 | -0.18 | -2.55% | 807.44M |
| NKSH | 29.00 | -0.96 | -3.20% | 207.92M |
| NKO | 14.93 | +0.05 | +0.32% | |
| NKE | 108.61 | -2.31 | -2.08% | 50.84B |
| NKBP | 4.50 | -0.16 | -3.43% | 89.66M |
| NKA | 11.67 | -0.28 | -2.34% | 412.16M |
| NJR | 41.80 | -0.82 | -1.92% | 1.768B |
| NGSX | 0.37 | +0.00 | +0.00% | 11.07M |
| NGPC | 6.71 | +0.03 | +0.45% | 144.49M |
| NGLS | 40.45 | -0.92 | -2.22% | 3.764B |